Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in Ann Hematol

Retrieve available abstracts of 160 articles:
HTML format

Single Articles

    December 2022
  1. YANG TT, Song XL, Zhao YM, Ye BD, et al
    Outcome after allogeneic hematopoietic stem cell transplantation following Venetoclax-based therapy among AML and MDS patients.
    Ann Hematol. 2022;101:2731-2741.
    PubMed     Abstract available

  2. DIAMANTOPOULOS PT, Kontandreopoulou CN, Stafylidis C, Vlachopoulou D, et al
    Immunogenicity of a third dose of the BNT162b2 COVID-19 vaccine in patients with CLL: effects on treatment selection.
    Ann Hematol. 2022;101:2711-2717.
    PubMed     Abstract available

  3. ZHANG JY, Li Y, Ma YS, Sun XJ, et al
    Clinical characteristics and prognostic factors in intracranial hemorrhage patients with hematological diseases.
    Ann Hematol. 2022;101:2617-2625.
    PubMed     Abstract available

  4. NAJIMA Y, Tachibana T, Takeda Y, Koda Y, et al
    Dose-finding trial of azacitidine as post-transplant maintenance for high-risk MDS: a KSGCT prospective study.
    Ann Hematol. 2022;101:2719-2729.
    PubMed     Abstract available

  5. TAN X, Yuan H, Li D, Sun X, et al
    Clinical and prognostic role of 2-[(18)F]FDG PET/CT and sarcopenia in treatment-naive patients with T-cell lymphoblastic lymphoma.
    Ann Hematol. 2022;101:2699-2709.
    PubMed     Abstract available

    November 2022
  6. SULEMAN A, Tsui H, Ghorab Z, Lam PW, et al
    EBV-positive diffuse large B-cell lymphoma following alemtuzumab therapy for T-cell prolymphocytic leukemia.
    Ann Hematol. 2022 Nov 28. doi: 10.1007/s00277-022-05060.

  7. SUN H, Yan H, Yan Z, Zhu Y, et al
    Acute myeloid leukemia patients with NUP98::NSD1 showing initially poor treatment response can benefit from FLT3 inhibitors and venetoclax as well as HSCT.
    Ann Hematol. 2022 Nov 24. doi: 10.1007/s00277-022-05047.

  8. BERDEL AF, Koch R, Gerss J, Hentrich M, et al
    A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy.
    Ann Hematol. 2022 Nov 18. pii: 10.1007/s00277-022-05025.
    PubMed     Abstract available

  9. ZHANG YW, Su L, Tan YH, Lin H, et al
    Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia.
    Ann Hematol. 2022 Nov 15. pii: 10.1007/s00277-022-05033.
    PubMed     Abstract available

  10. DELEHAYE F, Rouger J, Brossier D, Suttorp M, et al
    Prevalence of anemia at diagnosis of pediatric chronic myeloid leukemia and prognostic impact on the disease course.
    Ann Hematol. 2022 Nov 12. pii: 10.1007/s00277-022-05024.
    PubMed     Abstract available

  11. WELLER MC, Haralambieva E, Buhler MM, Benz R, et al
    CALR loss-of-heterozygosity as a potential driver for extramedullary AML.
    Ann Hematol. 2022;101:2571-2573.

  12. ZHU Y, Dai Y, Tang X
    Venetoclax combined with decitabine and HAAG regimen: a novel salvage strategy for relapsed/refractory T-cell acute lymphoblastic leukaemia.
    Ann Hematol. 2022;101:2525-2528.

    October 2022
  13. CORDELLA S, Parisotto A, Bettelli F, Morselli M, et al
    Feasibility of autologous peripheral blood stem cell mobilization and harvest in adult patients with FLT3-mutated acute myeloid leukemia receiving chemotherapy combined with midostaurin: a single-center experience.
    Ann Hematol. 2022 Oct 20. pii: 10.1007/s00277-022-05013.

  14. PARK HS, Kim HK, Kim HS, Yang Y, et al
    The new diagnostic criteria for myelodysplasia-related acute myeloid leukemia is useful for predicting clinical outcome: comparison of the 4th and 5th World Health Organization classifications.
    Ann Hematol. 2022 Oct 12. pii: 10.1007/s00277-022-05002.
    PubMed     Abstract available

  15. TRIGUERO A, Pedraza A, Perez-Encinas M, Mata-Vazquez MI, et al
    Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera.
    Ann Hematol. 2022;101:2231-2239.
    PubMed     Abstract available

  16. LIN SC, Yao CY, Hsu CA, Lin CT, et al
    Functional association of NR4A3 downregulation with impaired differentiation in myeloid leukemogenesis.
    Ann Hematol. 2022;101:2209-2218.
    PubMed     Abstract available

  17. WATANABE N, Takaku T, Fujioka I, Tsuchiya S, et al
    Bosutinib-induced late-onset severe liver injury preceded by eosinophilia.
    Ann Hematol. 2022;101:2257-2262.
    PubMed     Abstract available

  18. ZHANG H, Zhan Q, Wang X, Gao F, et al
    TLS/FUS-ERG fusion gene in acute leukemia and myelodysplastic syndrome evolved to acute leukemia: report of six cases and a literature review.
    Ann Hematol. 2022 Oct 1. pii: 10.1007/s00277-022-04979.
    PubMed     Abstract available

    September 2022
  19. SPATH C, Schonau M, Gaubert S, Neumann T, et al
    Rhabdomyolysis induced by nelarabine.
    Ann Hematol. 2022;101:2111-2112.

    August 2022
  20. HARADA N, Makuuchi Y, Kuno M, Takakuwa T, et al
    Intramural esophageal hematoma precipitated by acquired factor XI deficiency in a patient with relapsed T cell prolymphocytic leukemia after allogeneic hematopoietic cell transplantation.
    Ann Hematol. 2022 Aug 31. pii: 10.1007/s00277-022-04970.

  21. SAUGUES S, Lambert C, Daguenet E, Ansah HJ, et al
    Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory.
    Ann Hematol. 2022 Aug 30. pii: 10.1007/s00277-022-04955.
    PubMed     Abstract available

  22. MASETTI R, Muratore E, Gori D, Prete A, et al
    Allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia in first complete remission: a meta-analysis.
    Ann Hematol. 2022 Aug 30. pii: 10.1007/s00277-022-04965.
    PubMed     Abstract available

  23. LUNA A, Perez-Lamas L, Boque C, Giraldo P, et al
    Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia.
    Ann Hematol. 2022 Aug 23. pii: 10.1007/s00277-022-04932.
    PubMed     Abstract available

  24. GIAMMARCO S, Bellesi S, Metafuni E, Rossi M, et al
    Cord blood resilience in a patient with relapsing Ph + B lymphoblastic acute leukemia after hematopoietic stem cell transplantation.
    Ann Hematol. 2022 Aug 22. pii: 10.1007/s00277-022-04962.

  25. YANADA M
    Treatment for relapsed acute promyelocytic leukemia.
    Ann Hematol. 2022 Aug 16. pii: 10.1007/s00277-022-04954.
    PubMed     Abstract available

  26. ZHAI Y, Shang J, Yao W, Wu D, et al
    Successful eradication of central nervous system infiltration of primary plasma cell leukemia by temozolomide.
    Ann Hematol. 2022 Aug 15. pii: 10.1007/s00277-022-04942.

  27. CHIRICHES C, Khan D, Wieske M, Guillen N, et al
    Activation of signaling pathways in models of t(6;9)-acute myeloid leukemia.
    Ann Hematol. 2022 Aug 8. pii: 10.1007/s00277-022-04905.
    PubMed     Abstract available

  28. BOEREKAMPS A, Hamberg P, Libourel EJ
    Discontinuation of azacitidine in acute myeloid leukemia: a feasible option?
    Ann Hematol. 2022 Aug 4. pii: 10.1007/s00277-022-04939.

  29. DONG T, Wu N, Gao H, Liang S, et al
    CD277 agonist enhances the immunogenicity of relapsed/refractory acute myeloid leukemia towards Vdelta2(+) T cell cytotoxicity.
    Ann Hematol. 2022 Aug 3. pii: 10.1007/s00277-022-04930.
    PubMed     Abstract available

  30. ROTTERDAM J, Thiaucourt M, Weiss C, Schwaab J, et al
    Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases.
    Ann Hematol. 2022;101:1825-1834.
    PubMed     Abstract available

  31. WANG W, Zhang Y, Zhao D, Zhang W, et al
    Richter's syndrome in central nervous system with MYD88L265P and CD79b mutation responded well to ibrutinib containing chemotherapy: a case report and review of the literature.
    Ann Hematol. 2022;101:1869-1872.

    July 2022
  32. AHMED MZ, Venkatadasari I, Dyer S, Wall K, et al
    Clonal evolution in adult TCF3::HLF-positive acute lymphoblastic leukemia undergoing stem cell transplantation.
    Ann Hematol. 2022 Jul 30. pii: 10.1007/s00277-022-04941.

  33. SEVINDIK OG, Mergen M, Mergen S, Mutlu YG, et al
    To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission.
    Ann Hematol. 2022 Jul 29. pii: 10.1007/s00277-022-04938.

  34. SHIMONY S, Canaani J, Kugler E, Nachmias B, et al
    Correction to: Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a realworld, multicenter, matched analysis.
    Ann Hematol. 2022 Jul 23. pii: 10.1007/s00277-022-04929.

  35. SHIN WY, Kim JA, Yoon SY, Bang HI, et al
    Co-existence of a novel translocation t(11;22)(q23;q12.1) with PML-RARA in acute promyelocytic leukemia: a case report.
    Ann Hematol. 2022 Jul 2. pii: 10.1007/s00277-022-04911.

  36. WU X, Cheng L, Liu X, Sun Y, et al
    Clinical characteristics and outcomes of 100 adult patients with pure red cell aplasia.
    Ann Hematol. 2022;101:1493-1498.
    PubMed     Abstract available

  37. HIRANO M, Tamba M, Inoue N, Ikegami M, et al
    Durable response of therapy-related MDS/AML with concomitant Waldenstrom's macroglobulinemia treated with venetoclax and azacitidine.
    Ann Hematol. 2022;101:1587-1589.

    June 2022
  38. YIN J, Zhu F, Zhang ZB, Wang Q, et al
    Rapid and deep response to avapritinib in heavily treated acute myeloid leukemia with t (8;21) and KIT mutation.
    Ann Hematol. 2022 Jun 29. pii: 10.1007/s00277-022-04897.

  39. SHIMONY S, Canaani J, Kugler E, Nachmias B, et al
    Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis.
    Ann Hematol. 2022 Jun 24. pii: 10.1007/s00277-022-04895.
    PubMed     Abstract available

  40. WOLACH O, Frisch A, Shargian L, Yeshurun M, et al
    Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis.
    Ann Hematol. 2022 Jun 23. pii: 10.1007/s00277-022-04883.
    PubMed     Abstract available

  41. KATHPALIA M, Mishra P, Bajpai R, Bhurani D, et al
    Efficacy and safety of nelarabine in patients with relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis.
    Ann Hematol. 2022 Jun 21. pii: 10.1007/s00277-022-04880.
    PubMed     Abstract available

  42. YANG X, Zhang R, Zhang Z
    The rare IRF2BP2-RARA fusion in acute promyelocytic leukemia.
    Ann Hematol. 2022 Jun 15. pii: 10.1007/s00277-022-04874.

  43. BRAITSCH K, Schwarz A, Koch K, Hubbuch M, et al
    Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis.
    Ann Hematol. 2022;101:1311-1319.
    PubMed     Abstract available

  44. WATTEBLED KJ, Drumez E, Coiteux V, Magro L, et al
    Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation.
    Ann Hematol. 2022;101:1321-1331.
    PubMed     Abstract available

  45. LEUNG WY, Cheuk DK, Cheng FW, Leung AW, et al
    Outcome prediction of chronic myeloid leukemia (CML) in children.
    Ann Hematol. 2022 Jun 1. pii: 10.1007/s00277-022-04852.
    PubMed     Abstract available

    May 2022
  46. OCHS MA, Marini BL, Perissinotti AJ, Foucar CE, et al
    Oncology stewardship in acute myeloid leukemia.
    Ann Hematol. 2022 May 26. pii: 10.1007/s00277-022-04872.
    PubMed     Abstract available

  47. SAITO K, Ichikawa S, Ohtomo R, Hatta S, et al
    Severe platelet transfusion refractoriness due to anti-HPA-5a antibody during induction chemotherapy for acute promyelocytic leukemia.
    Ann Hematol. 2022 May 25. pii: 10.1007/s00277-022-04875.

  48. KOSCHADE SE, Stratmann JA, Finkelmeier F, Wagner S, et al
    Relapse surveillance of acute myeloid leukemia patients in first remission after consolidation chemotherapy: diagnostic value of regular bone marrow aspirations.
    Ann Hematol. 2022 May 20. pii: 10.1007/s00277-022-04862.
    PubMed     Abstract available

  49. ZENG Q, Xiang B, Liu Z
    Autologous hematopoietic stem cell transplantation followed by interleukin-2 for adult acute myeloid leukemia patients with favorable or intermediate risk after complete remission.
    Ann Hematol. 2022 May 16. pii: 10.1007/s00277-022-04863.
    PubMed     Abstract available

  50. PODVIN B, Guermouche H, Roynard P, Goursaud L, et al
    Subclonal acquisition of a BCR::ABL1 fusion in a chronic myelomonocytic leukemia.
    Ann Hematol. 2022 May 13. pii: 10.1007/s00277-022-04861.

  51. SHARMA R, Jani C
    Mapping incidence and mortality of leukemia and its subtypes in 21 world regions in last three decades and projections to 2030.
    Ann Hematol. 2022 May 10. pii: 10.1007/s00277-022-04843.
    PubMed     Abstract available

  52. BOQUOI A, Banahan SM, Mohring A, Savickaite I, et al
    Therapy-related myeloid neoplasms following treatment for multiple myeloma-a single center analysis.
    Ann Hematol. 2022;101:1031-1038.
    PubMed     Abstract available

  53. HOFER KD, Schanz U, Schwotzer R, Nair G, et al
    Real-world outcomes in elderly ALL patients with and without allogeneic hematopoietic stem cell transplantation: a single-center evaluation over 10 years.
    Ann Hematol. 2022;101:1097-1106.
    PubMed     Abstract available

  54. WANG Y, Hou W, Li H, Tian X, et al
    Analysis of risk factors for early death in patients with acute promyelocytic leukaemia treated with arsenic trioxide.
    Ann Hematol. 2022;101:1039-1047.
    PubMed     Abstract available

  55. SATO M, Yasunaga M, Ohzu M, Toyama K, et al
    Successful diagnosis of veno-occlusive disease caused by inotuzumab ozogamicin through minimal-invasive angiography: a case report.
    Ann Hematol. 2022;101:1153-1155.

  56. HAZENBERG CLE, Diepstra A, Santing M, Huls GA, et al
    Bone marrow necrosis as complication of treatment with all-trans retinoic acid and arsenic trioxide: case report and implications for treatment.
    Ann Hematol. 2022;101:1133-1134.

  57. SHALLIS RM, Pucar D, Perincheri S, Gore SD, et al
    Molecular testing of isolated myeloid sarcoma allows successful FLT3-targeted therapy.
    Ann Hematol. 2022;101:1145-1147.

    April 2022
  58. SEKERES MA, Schuster M, Joris M, Krauter J, et al
    A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.
    Ann Hematol. 2022 Apr 30. pii: 10.1007/s00277-022-04853.
    PubMed     Abstract available

  59. LI Y, Tang T, Xiao J, Li B, et al
    Comparative efficacy and safety of eleven induction chemotherapy regimens for young adult patients with newly diagnosed acute myeloid leukemia: a network meta-analysis.
    Ann Hematol. 2022 Apr 20. pii: 10.1007/s00277-022-04840.
    PubMed     Abstract available

  60. WANG Y, Wang T, Yu Y, Wang Q, et al
    Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant.
    Ann Hematol. 2022 Apr 18. pii: 10.1007/s00277-022-04795.
    PubMed     Abstract available

  61. LAUW MIS, Hakim N, Arora S, Prakash S, et al
    A case of plasma cell neoplasm-associated chronic neutrophilic leukemia with ASXL1 and JAK2V617F mutations.
    Ann Hematol. 2022 Apr 14. pii: 10.1007/s00277-022-04834.

  62. GREINER SM, Marklin M, Holzmayer S, Kaban K, et al
    Identification of CD105 (endoglin) as novel risk marker in CLL.
    Ann Hematol. 2022;101:773-780.
    PubMed     Abstract available

    March 2022
  63. MORIMOTO S, Kondo T, Taya T, Matsuo H, et al
    Successful allogeneic bone marrow transplantation in a case of variant acute promyelocytic leukemia with ZBTB16-RARA.
    Ann Hematol. 2022 Mar 26. pii: 10.1007/s00277-022-04825.

  64. LI Y, Dai H, Yao D, Gao X, et al
    Central nervous system relapse of acute promyelocytic leukemia treated by oral Venetoclax with Azacitidine achieved complete remission.
    Ann Hematol. 2022 Mar 26. pii: 10.1007/s00277-022-04823.

  65. TSUSHIMA T, Sato N, Guo YM, Uchiyama S, et al
    Combination therapy with low doses of ponatinib and steroids in elderly and frail patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ann Hematol. 2022 Mar 24. pii: 10.1007/s00277-022-04796.

  66. CHAUHAN P, Gupta A, Gopinathan M, Sanjeev, et al
    Real-world challenges in the management of acute myeloid leukemia: a single-center experience from North India.
    Ann Hematol. 2022 Mar 24. pii: 10.1007/s00277-022-04814.
    PubMed     Abstract available

  67. UMINSKI K, Khalife R, Kekre N, Tinmouth A, et al
    Acquired hemophilia A following allogeneic stem cell transplantation for acute lymphoblastic leukemia.
    Ann Hematol. 2022 Mar 21. pii: 10.1007/s00277-022-04819.

  68. CAETANO DOS SANTOS FL, Michalek IM, Wojciechowska U, Didkowska J, et al
    Improved survival of Burkitt lymphoma/leukemia patients: observations from Poland, 1999-2020.
    Ann Hematol. 2022 Mar 15. pii: 10.1007/s00277-022-04758.
    PubMed     Abstract available

  69. BI X, French Z, Palmisiano N, Wen KY, et al
    The prognostic impact of cigarette smoking on survival in acute myeloid leukemia with TP53 mutations and/or 17p deletions.
    Ann Hematol. 2022 Mar 14. pii: 10.1007/s00277-022-04812.
    PubMed     Abstract available

  70. ROBIN JB, Theron A, Quittet P, Exbrayat C, et al
    Discontinuation of tyrosine kinase inhibitor in chronic myeloid leukemia: a retrospective cohort in east occitania.
    Ann Hematol. 2022 Mar 12. pii: 10.1007/s00277-022-04779.
    PubMed     Abstract available

  71. ROSETTI M, De la Salle B, Farneti G, Clementoni A, et al
    The added value of digital morphological analysis in the evaluation of peripheral blood films: the report of an UKNEQAS external quality assessment sample.
    Ann Hematol. 2022;101:729-730.

    February 2022
  72. HERMEL DJ, Cheng B, Bhangoo MS, Burian C, et al
    Long-term outcomes of elderly hairy cell leukemia patients treated with cladribine.
    Ann Hematol. 2022 Feb 26. pii: 10.1007/s00277-022-04800.
    PubMed     Abstract available

  73. BAYSAL M, Gursoy V, Hunutlu FC, Erkan B, et al
    The evaluation of risk factors leading to early deaths in patients with acute promyelocytic leukemia: a retrospective study.
    Ann Hematol. 2022 Feb 21. pii: 10.1007/s00277-022-04798.
    PubMed     Abstract available

  74. ROBAK E, Jesionek-Kupnicka D, Stelmach P, Kupnicki P, et al
    Leukemia cutis in accelerated chronic lymphocytic leukemia: successful treatment with venetoclax and rituximab.
    Ann Hematol. 2022 Feb 21. pii: 10.1007/s00277-022-04753.

  75. TANG G, Zou Y, Wang SA, Borthakur G, et al
    3'CBFB deletion in CBFB-rearranged acute myeloid leukemia retains morphological features associated with inv(16), but patients have higher risk of relapse and may require stem cell transplant.
    Ann Hematol. 2022 Feb 20. pii: 10.1007/s00277-022-04767.
    PubMed     Abstract available

  76. FU W, Huang A, Tang G, Yang J, et al
    A case report of BCR-ABL1 rearrangement in de novo adult T-cell lymphoblastic leukemia/lymphoma with normal karyotype.
    Ann Hematol. 2022 Feb 14. pii: 10.1007/s00277-022-04791.

  77. MARTELLA F, Cerrano M, Di Cuonzo D, Secreto C, et al
    Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study.
    Ann Hematol. 2022 Feb 7. pii: 10.1007/s00277-022-04770.
    PubMed     Abstract available

  78. KEREN-FROIM N, Heering G, Sharvit G, Zlotnik M, et al
    ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapy.
    Ann Hematol. 2022;101:309-316.
    PubMed     Abstract available

  79. SCHMITZ-FEUERHAKE I, Frentzel-Beyme R, Wolff R
    Non-Hodgkin lymphomas and ionizing radiation: case report and review of the literature.
    Ann Hematol. 2022;101:243-250.
    PubMed     Abstract available

  80. DI GIACOMO D, Quintini M, Pierini V, Pellanera F, et al
    Genomic and clinical findings in myeloid neoplasms with PDGFRB rearrangement.
    Ann Hematol. 2022;101:297-307.
    PubMed     Abstract available

  81. DUNN WG, Gu MS, Fabre MA, Cooper J, et al
    The PML-RARA fusion is not detectable in historical blood samples of acute promyelocytic leukaemia patients.
    Ann Hematol. 2022;101:443-445.

    January 2022
  82. BAEK J, Kim MK, Gu MJ
    Myelolipoma/extramedullary hematopoiesis within adrenal cortical adenoma increased in size during chronic myelogenous leukemia treatment.
    Ann Hematol. 2022 Jan 28. pii: 10.1007/s00277-022-04768.

  83. FREDMAN D, Moshe Y, Wolach O, Heering G, et al
    Evaluating outcomes of adult patients with acute lymphoblastic leukemia and lymphoblastic lymphoma treated on the GMALL 07/2003 protocol.
    Ann Hematol. 2022 Jan 28. pii: 10.1007/s00277-021-04738.
    PubMed     Abstract available

  84. QIU L, Nunez CA, Tang G, Cuglievan B, et al
    A rare case of acute megakaryoblastic leukemia with t(11;17)(q23;q21) and KMT2A::MLLT6 fusion.
    Ann Hematol. 2022 Jan 28. pii: 10.1007/s00277-022-04769.

  85. MELLADO-GAZQUEZ A, Gomez-Nunez MR, Jurado-Herrera S, Prats-Martin C, et al
    Multiple erythrophagocytosis by erythroid blasts in acute myeloid leukemia with BCR-ABL1.
    Ann Hematol. 2022 Jan 27. pii: 10.1007/s00277-021-04742.

  86. DUTTA S, Moritz J, Pregartner G, Thallinger GG, et al
    Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations.
    Ann Hematol. 2022 Jan 26. pii: 10.1007/s00277-022-04766.
    PubMed     Abstract available

  87. MAO YY, Cai HC, Shen KN, Chang L, et al
    Benefit of high-dose idarubicin as induction therapy in acute myeloid leukemia: a prospective phase 2 study.
    Ann Hematol. 2022 Jan 17. pii: 10.1007/s00277-022-04764.
    PubMed     Abstract available

  88. ONISHI A, Fuji S, Kitano S, Maeshima AM, et al
    Prognostic implication of CTLA-4, PD-1, and PD-L1 expression in aggressive adult T-cell leukemia-lymphoma.
    Ann Hematol. 2022 Jan 15. pii: 10.1007/s00277-022-04760.
    PubMed     Abstract available

  89. TISO F, Koorenhof-Scheele TN, Huys E, Martens JHA, et al
    Genetic diversity within leukemia-associated immunophenotype-defined subclones in AML.
    Ann Hematol. 2022 Jan 13. pii: 10.1007/s00277-021-04747.
    PubMed     Abstract available

  90. HARADA K, Mizuno S, Yano S, Takami A, et al
    Donor lymphocyte infusion after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia.
    Ann Hematol. 2022 Jan 6. pii: 10.1007/s00277-021-04731.
    PubMed     Abstract available

  91. ZEIDAN AM, DeAngelo DJ, Palmer J, Seet CS, et al
    Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
    Ann Hematol. 2022 Jan 4. pii: 10.1007/s00277-021-04734.
    PubMed     Abstract available

  92. KONUMA T, Ooi J, Nagayama H, Tomonari A, et al
    Long-term outcomes following the addition of granulocyte colony-stimulating factor-combined high-dose cytarabine to total body irradiation and cyclophosphamide conditioning in single-unit cord blood transplantation for myeloid malignancies.
    Ann Hematol. 2022;101:177-189.
    PubMed     Abstract available

  93. GUPTA A, Desai N, Sanjeev, Chauhan P, et al
    Clinical profile and outcome of COVID-19 in haematological malignancies: experience from tertiary care centre in India.
    Ann Hematol. 2022;101:69-79.
    PubMed     Abstract available

  94. SAKURAI M, Nannya Y, Yamazaki R, Yamaguchi K, et al
    Germline RUNX1 translocation in familial platelet disorder with propensity to myeloid malignancies.
    Ann Hematol. 2022;101:237-239.

    December 2021
  95. DALELA D, Bledsoe JR, Patel SA
    Clonal IgH gene rearrangements identify Richter's transformation to diffuse large B cell lymphoma.
    Ann Hematol. 2021;100:3075-3077.

  96. PULIDO-PEREZ A, Bergon-Sendin M, Mateos-Mayo A, Parra-Blanco V, et al
    Cutaneous botryomycosis mimicking ecthyma gangrenosum in a patient treated with ibrutinib.
    Ann Hematol. 2021;100:3065-3066.

    November 2021
  97. ARCANI R, Colle J, Cauchois R, Koubi M, et al
    Clinical characteristics and outcomes of patients with haematologic malignancies and COVID-19 suggest that prolonged SARS-CoV-2 carriage is an important issue.
    Ann Hematol. 2021;100:2799-2803.
    PubMed     Abstract available

  98. REINERT J, Beitzen-Heineke A, Wethmar K, Stelljes M, et al
    Loss of CD22 expression and expansion of a CD22(dim) subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin.
    Ann Hematol. 2021;100:2727-2732.
    PubMed     Abstract available

  99. MAYER MC, Berg JL, Perfler B, Hatzl S, et al
    miR-23a mediates resistance to hypomethylating agents in myeloid neoplasms.
    Ann Hematol. 2021;100:2845-2847.

    October 2021
  100. STANGANELLI C, Torres DC, Ortega C, Marquez ME, et al
    Somatic hypermutation profiles in stereotyped IGHV4-34 receptors from South American chronic lymphocytic leukemia patients.
    Ann Hematol. 2021 Oct 28. pii: 10.1007/s00277-021-04703.
    PubMed     Abstract available

  101. MENDES FR, da Silva WF, da Costa Bandeira de Melo R, Silveira DRA, et al
    Predictive factors associated with induction-related death in acute myeloid leukemia in a resource-constrained setting.
    Ann Hematol. 2021 Oct 21. pii: 10.1007/s00277-021-04687.
    PubMed     Abstract available

  102. ZHANG Y, Qian JJ, Shen YJ, Hang SJ, et al
    The first report of complete remission following treatment with venetoclax plus prednisone in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Ann Hematol. 2021 Oct 18. pii: 10.1007/s00277-021-04699.

  103. HOU HA, Tzeng HE, Liu HY, Chou WC, et al
    Effectiveness of induction regimens on survival outcome in acute myeloid leukemia patients: a real-world data from 2001 to 2015.
    Ann Hematol. 2021 Oct 13. pii: 10.1007/s00277-021-04670.
    PubMed     Abstract available

  104. PASVOLSKY O, Shimony S, Ram R, Shimoni A, et al
    Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.
    Ann Hematol. 2021 Oct 9. pii: 10.1007/s00277-021-04693.
    PubMed     Abstract available

  105. UMINSKI K, Khalife R, Fulcher J, Duffett L, et al
    Acquired factor V deficiency in the setting of mercaptopurine therapy for acute lymphoblastic leukemia.
    Ann Hematol. 2021 Oct 6. pii: 10.1007/s00277-021-04688.

  106. CHOI HS, Hong J, Hwang SM, Lee JH, et al
    Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms.
    Ann Hematol. 2021;100:2567-2574.
    PubMed     Abstract available

  107. SHAH N, Rakszawski K, Nickolich M, Ehmann C, et al
    Improved outcome in AML relapse after allogeneic transplant with high-intensity chemotherapy followed by 2nd allogeneic stem cell transplant or donor lymphocyte infusion.
    Ann Hematol. 2021;100:2585-2592.
    PubMed     Abstract available

  108. BALLO O, Eladly F, Koschade S, Buttner S, et al
    Fluid overload is associated with increased 90-day mortality in AML patients undergoing induction chemotherapy.
    Ann Hematol. 2021;100:2603-2611.
    PubMed     Abstract available

  109. DAS N, Gupta R, Gupta SK, Bakhshi S, et al
    Critical evaluation of the utility of pre- and post-therapy immunophenotypes in assessment of measurable residual disease in B-ALL.
    Ann Hematol. 2021;100:2487-2500.
    PubMed     Abstract available

  110. SAVASAN S, Buck S, Gadgeel M, Poulik J, et al
    Persistent pseudo-Pelger-Huet anomaly.
    Ann Hematol. 2021;100:2661-2663.

  111. MARRA A, Martino G, Scarpelli N, Perriello V, et al
    Collision diffuse large B cell lymphoma and myeloid sarcoma in the liver.
    Ann Hematol. 2021;100:2649-2651.

    September 2021
  112. KIM TH, Choi YW, Ahn MS, Choi YS, et al
    Early removal of central venous catheter may not impact the in-hospital mortality in patients with acute leukemia.
    Ann Hematol. 2021 Sep 30. pii: 10.1007/s00277-021-04673.
    PubMed     Abstract available

  113. ZHAO P, Ni M, Ma D, Fang Q, et al
    Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2021 Sep 27. pii: 10.1007/s00277-021-04674.
    PubMed     Abstract available

  114. FAGUNDES EM, Neto NN, Caldas LM, Aragao JR, et al
    Mortality by COVID-19 in adults with acute myeloid leukemia: a survey with hematologists in Brazil.
    Ann Hematol. 2021 Sep 17. pii: 10.1007/s00277-021-04659.

  115. XU RZ, Karsan A, Xu Z, Berry BR, et al
    A rare de novo pure erythroid leukemia with JAK2 R683S mutation.
    Ann Hematol. 2021 Sep 4. pii: 10.1007/s00277-021-04657.

  116. YANADA M, Konuma T, Yamasaki S, Mizuno S, et al
    The differential effect of disease status at allogeneic hematopoietic cell transplantation on outcomes in acute myeloid and lymphoblastic leukemia.
    Ann Hematol. 2021 Sep 3. pii: 10.1007/s00277-021-04661.
    PubMed     Abstract available

  117. FUJI S, Kida S, Nakata K, Morishima T, et al
    Long-term trends in the clinical outcomes of patients with acute myeloid leukemia: a population-based real-world data analysis using the Osaka Cancer Registry.
    Ann Hematol. 2021 Sep 3. pii: 10.1007/s00277-021-04631.
    PubMed     Abstract available

  118. HEINICKE T, Krahl R, Kahl C, Cross M, et al
    Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials.
    Ann Hematol. 2021;100:2387-2398.
    PubMed     Abstract available

  119. QI J, Zhang R, Cai C, Wang H, et al
    HLA-DQB1 mismatch increase risk of severe bleeding independently in recipients of allogeneic stem cell transplant.
    Ann Hematol. 2021;100:2351-2361.
    PubMed     Abstract available

  120. CHEN X, Liu C, Zhang A, Wu W, et al
    Low absolute neutrophil count during induction therapy is an adverse prognostic factor in childhood acute lymphoblastic leukaemia.
    Ann Hematol. 2021;100:2269-2277.
    PubMed     Abstract available

  121. SIM JPY, Lie AKW, Ng MY, Kwong YL, et al
    Durable remission of T cell lymphoblastic lymphoma relapsing after allogeneic haematopoietic stem cell transplantation with a single low dose of nivolumab.
    Ann Hematol. 2021;100:2399-2402.

    August 2021
  122. GUERY R, Suarez F, Lanternier F, Bougnoux ME, et al
    Poor outcome and high prevalence of invasive fungal infections in patients with adult T-cell leukemia/lymphoma exposed to zidovudine and interferon alfa.
    Ann Hematol. 2021 Aug 13. pii: 10.1007/s00277-021-04622.
    PubMed     Abstract available

  123. TACHIBANA T, Kanda J, Ishizaki T, Najima Y, et al
    Pre-conditioning intervention in patients with relapsed or refractory acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation: a KSGCT multicenter retrospective analysis.
    Ann Hematol. 2021 Aug 6. pii: 10.1007/s00277-021-04607.
    PubMed     Abstract available

  124. MIAN AA, Haberbosch I, Khamaisie H, Agbarya A, et al
    Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K).
    Ann Hematol. 2021;100:2023-2029.
    PubMed     Abstract available

  125. WELLBROCK J, Behrmann L, Muschhammer J, Modemann F, et al
    The BET bromodomain inhibitor ZEN-3365 targets the Hedgehog signaling pathway in acute myeloid leukemia.
    Ann Hematol. 2021 Aug 1. pii: 10.1007/s00277-021-04602.
    PubMed     Abstract available

    July 2021
  126. MI R, Chen L, Yang H, Zhang Y, et al
    Combined use of interferon alpha-1b, interleukin-2, and thalidomide to reverse the AML1-ETO fusion gene in acute myeloid leukemia.
    Ann Hematol. 2021 Jul 27. pii: 10.1007/s00277-021-04621.
    PubMed     Abstract available

  127. MATSUDA K, Jo T, Toyama K, Nakazaki K, et al
    Risk factors for early in-hospital death in patients who developed coagulopathy during induction therapy for acute promyelocytic leukemia: a nationwide analysis in Japan.
    Ann Hematol. 2021 Jul 26. pii: 10.1007/s00277-021-04620.
    PubMed     Abstract available

  128. ALRAWASHDH N, Sweasy J, Erstad B, McBride A, et al
    Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985-2017).
    Ann Hematol. 2021 Jul 19. pii: 10.1007/s00277-021-04600.
    PubMed     Abstract available

  129. ELNAIR R, Ellithi M, Kallam A, Shostrom V, et al
    Outcomes of Richter's transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an analysis of the SEER database.
    Ann Hematol. 2021 Jul 19. pii: 10.1007/s00277-021-04603.
    PubMed     Abstract available

  130. KONG J, Qin YZ, Zhao XS, Hou Y, et al
    Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment.
    Ann Hematol. 2021 Jul 19. pii: 10.1007/s00277-021-04606.
    PubMed     Abstract available

  131. MICHAELIS S, Pichler A, Stelzer I, Schoffmann L, et al
    Aggressive NK-cell leukemia with hemophagocytosis in a Caucasian patient.
    Ann Hematol. 2021 Jul 16. pii: 10.1007/s00277-021-04585.

  132. HARA R, Onizuka M, Kikkawa E, Shiraiwa S, et al
    Association between measurable residual disease kinetics and outcomes of Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ann Hematol. 2021 Jul 11. pii: 10.1007/s00277-021-04587.
    PubMed     Abstract available

  133. BARZEGAR M, Farsani MA, Rafiee M, Amiri V, et al
    Acute promyelocytic leukemia derived extracellular vesicles conserve PML-RARalpha transcript from storage-inflicted degradation: a stable diagnosis tool in APL patients.
    Ann Hematol. 2021 Jul 8. pii: 10.1007/s00277-021-04579.
    PubMed     Abstract available

  134. TANIGAWA T, Sakurai M, Kato J, Mizuno K, et al
    Successful ibrutinib treatment for central nervous system relapse of chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2021 Jul 8. pii: 10.1007/s00277-021-04586.

  135. GREIL R, Tedeschi A, Moreno C, Anz B, et al
    Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.
    Ann Hematol. 2021;100:1733-1742.
    PubMed     Abstract available

  136. GADGEEL M, AlQanber B, Buck S, Taub JW, et al
    Aberrant myelomonocytic CD56 expression in Down syndrome is frequent and not associated with leukemogenesis.
    Ann Hematol. 2021;100:1695-1700.
    PubMed     Abstract available

    June 2021
  137. VIRK H, Rana S, Sharma P, Bose PL, et al
    Hematological characteristics, cytogenetic features, and post-induction measurable residual disease in thymic stromal lymphopoietin receptor (TSLPR) overexpressed B-cell acute lymphoblastic leukemia in an Indian cohort.
    Ann Hematol. 2021 Jun 22. pii: 10.1007/s00277-021-04574.
    PubMed     Abstract available

  138. WYSOCKA-SLOWIK A, Gil L, Slebioda Z, Kregielczak A, et al
    Oral mucositis in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation in relation to the conditioning used prior to transplantation.
    Ann Hematol. 2021 Jun 12. pii: 10.1007/s00277-021-04568.
    PubMed     Abstract available

  139. KRECAK I, Cengic M, Skoric I, Nakic M, et al
    Concomitant autoimmune hemolytic anemia and pure red cell aplasia in a patient with chronic lymphocytic leukemia successfully treated with ibrutinib.
    Ann Hematol. 2021 Jun 10. pii: 10.1007/s00277-021-04570.

  140. DOU X, Zheng F, Zhang L, Jin J, et al
    Adolescents experienced more treatment failure than children with chronic myeloid leukemia receiving imatinib as frontline therapy: a retrospective multicenter study.
    Ann Hematol. 2021 Jun 5. pii: 10.1007/s00277-021-04544.
    PubMed     Abstract available

  141. AL-SARAYFI D, Meeuwes FO, Munnink TO, Plattel W, et al
    Successful treatment of hairy cell leukemia variant with obinutuzumab.
    Ann Hematol. 2021 Jun 4. pii: 10.1007/s00277-021-04559.

  142. LARIBI K, Sobh M, Ghez D, Baugier de Materre A, et al
    Impact of age, functional status, and comorbidities on quality of life and outcomes in elderly patients with AML: review.
    Ann Hematol. 2021;100:1359-1376.
    PubMed     Abstract available

  143. ZENG Z, Ly C, Daver N, Cortes J, et al
    High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells.
    Ann Hematol. 2021;100:1485-1496.
    PubMed     Abstract available

    May 2021
  144. HEUSER M, Smith BD, Fiedler W, Sekeres MA, et al
    Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
    Ann Hematol. 2021 May 12. pii: 10.1007/s00277-021-04545.

  145. KONG J, Chen N, Li M, Zhang J, et al
    Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia.
    Ann Hematol. 2021 May 6. pii: 10.1007/s00277-021-04530.

  146. DEVOS T, Havelange V, Theunissen K, Meers S, et al
    Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
    Ann Hematol. 2021 May 4. pii: 10.1007/s00277-021-04507.
    PubMed     Abstract available

  147. GONZALEZ JS, Perusini MA, Basquiera AL, Alfonso G, et al
    Prognostic assessment for chronic myelomonocytic leukemia in the context of the World Health Organization 2016 proposal: a multicenter study of 280 patients.
    Ann Hematol. 2021 May 1. pii: 10.1007/s00277-021-04539.
    PubMed     Abstract available

  148. SALAMONOWICZ-BODZIOCH M, Fraczkiewicz J, Czyzewski K, Zajac-Spychala O, et al
    Prospective analysis of BKV hemorrhagic cystitis in children and adolescents undergoing hematopoietic cell transplantation.
    Ann Hematol. 2021;100:1283-1293.
    PubMed     Abstract available

  149. TANG KHK, Ip AHW, Kwong YL
    Clonal derivation of sequential seminoma and acute megakaryoblastic leukaemia.
    Ann Hematol. 2021;100:1337-1339.

  150. HORIUCHI M, Yoshida M, Yamasaki K, Sakagami R, et al
    Effective treatment with imatinib for acute B-lymphoblastic leukaemia with EBF1-PDGFRB fusion.
    Ann Hematol. 2021;100:1329-1331.

  151. BERNARDI S, Zanaglio C, Farina M, Polverelli N, et al
    dsDNA from extracellular vesicles (EVs) in adult AML.
    Ann Hematol. 2021;100:1355-1356.

    April 2021
  152. MARTINEZ SANCHEZ MP, Megias-Vericat JE, Rodriguez-Veiga R, Vives S, et al
    A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients.
    Ann Hematol. 2021 Apr 29. pii: 10.1007/s00277-021-04542.
    PubMed     Abstract available

  153. ZHAO H, Sun J, Yan L, Jin B, et al
    Tissue factor-bearing microparticles are a link between acute promyelocytic leukemia cells and coagulation activation: a human subject study.
    Ann Hematol. 2021 Apr 24. pii: 10.1007/s00277-021-04533.
    PubMed     Abstract available

  154. KE P, Zhang X, Liu S, Zhu Q, et al
    The time-dependent effects of early-onset Epstein-Barr viremia on adult acute leukemia patients following allo-HSCT with ATG-containing MAC regimen.
    Ann Hematol. 2021 Apr 22. pii: 10.1007/s00277-021-04528.
    PubMed     Abstract available

  155. ONAKA T, Kato-Ogura A, Otsuka Y, Iwai F, et al
    A case report of combined treatment of gilteritinib and LH-RH agonist for Fms-related tyrosine kinase 3 receptor mutation-positive acute myeloid leukemia and bone marrow metastasis of prostate cancer.
    Ann Hematol. 2021 Apr 12. pii: 10.1007/s00277-021-04516.

  156. OWATTANAPANICH W, Herzig J, Jahn N, Panina E, et al
    Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome-excess blasts detected by next-generation sequencing technique.
    Ann Hematol. 2021 Apr 10. pii: 10.1007/s00277-021-04513.
    PubMed     Abstract available

  157. QIAN Y, Chen Y, Li X
    CSF3R T618I, SETBP1 G870S, SRSF2 P95H, and ASXL1 Q780* tetramutation co-contribute to myeloblast transformation in a chronic neutrophilic leukemia.
    Ann Hematol. 2021 Apr 6. pii: 10.1007/s00277-021-04491.
    PubMed     Abstract available

  158. RETTIG AR, Ihorst G, Bertz H, Lubbert M, et al
    Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis.
    Ann Hematol. 2021 Apr 1. pii: 10.1007/s00277-021-04494.
    PubMed     Abstract available

    January 2021
  159. LIU J, Shen L, Huang H, Gao X, et al
    A rare case of donor-derived promyelocytic sarcoma in a kidney transplant recipient.
    Ann Hematol. 2021;100:295-296.

    June 2020
  160. HOCHMAN MJ, Martin DB
    Coincidence of autoimmune hemolytic anemia and pure red cell aplasia in a patient with CLL.
    Ann Hematol. 2020 Jun 16. pii: 10.1007/s00277-020-04091.

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.